INOVIO PHARMACEUTICALS, INC. Financing Cash Flow
INOVIO PHARMACEUTICALS, INC. (INO) reported Financing Cash Flow of $18.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $17.16M.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $953.79K, a 7.21% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $27.13M, a 6.90% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $24.92M, a 3672.40% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $53.05M, a 3.06% increase from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $51.48M, a 930.52% increase from fiscal 2023.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $5.00M, a 93.90% decline from fiscal 2022.
- INOVIO PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $81.84M, a 61.30% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $18.11M 10-Q · filed 2026-08-12 | $45.24M derived: sum of 3 quarters · filed 2026-08-12 | $70.17M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $953.79K 10-Q · filed 2026-05-13 | $28.09M derived: sum of 2 quarters · filed 2026-05-13 | $53.01M derived: sum of 3 quarters · filed 2026-05-13 | $52.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $27.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $52.06M derived: sum of 2 quarters · filed 2026-03-12 | $52.02M derived: sum of 3 quarters · filed 2026-08-12 | $53.05M 10-K · filed 2026-03-12 |
| 2025-09-30 | $24.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $24.89M derived: sum of 2 quarters · filed 2026-08-12 | $25.92M 10-Q · filed 2025-11-10 | $55.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$34.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $993.15K 10-Q · filed 2026-08-12 | $30.14M derived: sum of 3 quarters · filed 2026-08-12 | $30.80M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.03M 10-Q · filed 2026-05-13 | $30.17M derived: sum of 2 quarters · filed 2026-05-13 | $30.83M derived: sum of 3 quarters · filed 2026-05-13 | $63.87M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $29.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $29.81M derived: sum of 2 quarters · filed 2026-03-12 | $62.84M derived: sum of 3 quarters · filed 2026-03-12 | $51.48M 10-K · filed 2026-03-12 |
| 2024-09-30 | $660.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $33.69M derived: sum of 2 quarters · filed 2025-11-10 | $22.33M 10-Q · filed 2025-11-10 | $24.17M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $33.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $21.67M 10-Q · filed 2025-08-12 | $23.51M derived: sum of 3 quarters · filed 2025-08-12 | $24.21M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$11.36M 10-Q · filed 2025-05-13 | -$9.53M derived: sum of 2 quarters · filed 2025-05-13 | -$8.83M derived: sum of 3 quarters · filed 2025-05-13 | -$5.94M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $2.54M derived: sum of 2 quarters · filed 2025-03-18 | $5.42M derived: sum of 3 quarters · filed 2025-03-18 | $5.00M 10-K · filed 2025-03-18 |
| 2023-09-30 | $698.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $3.58M derived: sum of 2 quarters · filed 2024-11-14 | $3.16M 10-Q · filed 2024-11-14 | $9.82M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.46M 10-Q · filed 2024-08-08 | $9.13M derived: sum of 3 quarters · filed 2024-08-08 | $12.94M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$424.70K 10-Q · filed 2024-05-13 | $6.24M derived: sum of 2 quarters · filed 2024-05-13 | $10.05M derived: sum of 3 quarters · filed 2024-05-13 | $52.99M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $10.48M derived: sum of 2 quarters · filed 2024-03-06 | $53.42M derived: sum of 3 quarters · filed 2024-03-06 | $81.84M 10-K · filed 2024-03-06 |
| 2022-09-30 | $3.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $46.75M derived: sum of 2 quarters · filed 2023-11-09 | $75.17M 10-Q · filed 2023-11-09 | $122.77M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $42.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $71.36M 10-Q · filed 2023-08-09 | $118.96M derived: sum of 3 quarters · filed 2024-03-06 | $118.52M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $28.42M 10-Q · filed 2023-05-10 | $76.02M derived: sum of 2 quarters · filed 2024-03-06 | $75.58M derived: sum of 3 quarters · filed 2024-03-06 | $79.02M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $47.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $47.15M derived: sum of 2 quarters · filed 2024-03-06 | $50.60M derived: sum of 3 quarters · filed 2024-03-06 | $211.50M 10-K · filed 2024-03-06 |
| 2021-09-30 | -$440.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $3.00M derived: sum of 2 quarters · filed 2022-11-08 | $163.90M 10-Q · filed 2022-11-08 | $290.84M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $164.34M 10-Q · filed 2022-08-09 | $291.28M derived: sum of 3 quarters · filed 2023-03-01 | $289.59M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $160.90M 10-Q · filed 2022-05-10 | $287.84M derived: sum of 2 quarters · filed 2023-03-01 | $286.15M derived: sum of 3 quarters · filed 2023-03-01 | $412.67M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $126.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $125.24M derived: sum of 2 quarters · filed 2023-03-01 | $251.77M derived: sum of 3 quarters · filed 2023-03-01 | $465.28M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $124.83M derived: sum of 2 quarters · filed 2021-11-09 | $338.34M 10-Q · filed 2021-11-09 | $347.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $126.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $340.04M 10-Q · filed 2021-08-09 | $349.68M derived: sum of 3 quarters · filed 2022-03-01 | $365.26M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $213.51M 10-Q · filed 2021-05-10 | $223.16M derived: sum of 2 quarters · filed 2022-03-01 | $238.74M derived: sum of 3 quarters · filed 2022-03-01 | $240.03M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $9.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $25.23M derived: sum of 2 quarters · filed 2022-03-01 | $26.52M derived: sum of 3 quarters · filed 2022-03-01 | $105.40M 10-K · filed 2022-03-01 |
| 2019-09-30 | $15.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $16.88M derived: sum of 2 quarters · filed 2020-11-09 | $95.75M 10-Q · filed 2020-11-09 | $110.15M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $80.17M 10-Q · filed 2020-08-10 | $94.57M derived: sum of 3 quarters · filed 2021-03-01 | $109.13M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $78.88M 10-Q · filed 2020-05-11 | $93.27M derived: sum of 2 quarters · filed 2021-03-01 | $107.84M derived: sum of 3 quarters · filed 2021-03-01 | $110.42M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $14.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $28.96M derived: sum of 2 quarters · filed 2021-03-01 | $31.54M derived: sum of 3 quarters · filed 2021-03-01 | $31.04M 10-K · filed 2021-03-01 |
| 2018-09-30 | $14.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $17.15M derived: sum of 2 quarters · filed 2019-11-12 | $16.64M 10-Q · filed 2019-11-12 | $16.52M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $2.08M 10-Q · filed 2019-08-08 | $1.95M derived: sum of 3 quarters · filed 2020-03-12 | $72.84M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$506.40K 10-Q · filed 2019-05-09 | -$631.08K derived: sum of 2 quarters · filed 2020-03-12 | $70.26M derived: sum of 3 quarters · filed 2020-03-12 | $94.36M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$124.68K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $70.76M derived: sum of 2 quarters · filed 2020-03-12 | $94.86M derived: sum of 3 quarters · filed 2020-03-12 | $95.69M 10-K · filed 2020-03-12 |
| 2017-09-30 | $70.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $94.99M derived: sum of 2 quarters · filed 2018-11-08 | $95.81M 10-Q · filed 2018-11-08 | $96.69M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $24.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $24.93M 10-Q · filed 2018-08-07 | $25.80M derived: sum of 3 quarters · filed 2019-03-12 | $30.17M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $826.44K 10-Q · filed 2018-05-09 | $1.70M derived: sum of 2 quarters · filed 2019-03-12 | $6.07M derived: sum of 3 quarters · filed 2019-03-12 | $8.54M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $870.31K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $5.24M derived: sum of 2 quarters · filed 2019-03-12 | $7.72M derived: sum of 3 quarters · filed 2019-03-12 | $7.79M 10-K · filed 2019-03-12 |
| 2016-09-30 | $4.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $6.85M derived: sum of 2 quarters · filed 2017-11-08 | $6.92M 10-Q · filed 2017-11-08 | $7.08M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $2.55M 10-Q · filed 2017-08-08 | $2.71M derived: sum of 3 quarters · filed 2018-03-14 | $4.43M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $69.48K 10-Q · filed 2017-05-10 | $228.89K derived: sum of 2 quarters · filed 2018-03-14 | $1.96M derived: sum of 3 quarters · filed 2018-03-14 | $84.42M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $159.41K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $1.89M derived: sum of 2 quarters · filed 2018-03-14 | $84.35M derived: sum of 3 quarters · filed 2018-03-14 | $84.35M 10-K · filed 2018-03-14 |
| 2015-09-30 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $84.19M derived: sum of 2 quarters · filed 2016-11-09 | $84.19M 10-Q · filed 2016-11-09 | $85.36M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $82.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $82.47M 10-Q · filed 2016-08-08 | $83.63M derived: sum of 3 quarters · filed 2017-03-15 | $84.13M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-09 | $1.17M derived: sum of 2 quarters · filed 2017-03-15 | $1.67M derived: sum of 3 quarters · filed 2017-03-15 | $2.57M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $1.67M derived: sum of 2 quarters · filed 2017-03-15 | $2.57M derived: sum of 3 quarters · filed 2017-03-15 | $72.46M 10-K · filed 2017-03-15 |
| 2014-09-30 | $498.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $1.40M derived: sum of 2 quarters · filed 2015-11-09 | $71.30M 10-Q · filed 2015-11-09 | $75.82M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $905.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $70.80M 10-Q · filed 2015-08-10 | $75.32M derived: sum of 3 quarters · filed 2016-03-14 | $103.92M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $69.89M 10-Q · filed 2015-05-11 | $74.41M derived: sum of 2 quarters · filed 2016-03-14 | $103.02M derived: sum of 3 quarters · filed 2016-03-14 | $103.02M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $33.12M derived: sum of 2 quarters · filed 2016-03-14 | $33.13M derived: sum of 3 quarters · filed 2016-03-14 | $52.69M 10-K · filed 2016-03-14 |
| 2013-09-30 | $28.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $28.61M derived: sum of 2 quarters · filed 2014-11-10 | $48.17M 10-Q · filed 2014-11-10 | $52.27M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | $5.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $19.57M 10-Q · filed 2014-08-11 | $23.67M derived: sum of 3 quarters · filed 2015-03-16 | $24.89M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | $19.56M 10-Q · filed 2014-05-12 | $23.66M derived: sum of 2 quarters · filed 2015-03-16 | $24.89M derived: sum of 3 quarters · filed 2015-03-16 | $24.89M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $5.33M derived: sum of 2 quarters · filed 2015-03-16 | $5.33M derived: sum of 3 quarters · filed 2015-03-16 | $5.33M 10-K · filed 2015-03-16 |
| 2012-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $1.23M derived: sum of 2 quarters · filed 2013-11-12 | $1.23M 10-Q · filed 2013-11-12 | $4.91M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $0.00 10-Q · filed 2013-08-09 | $3.69M derived: sum of 3 quarters · filed 2014-03-17 | $3.69M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $0.00 10-Q · filed 2013-05-10 | $3.69M derived: sum of 2 quarters · filed 2014-03-17 | $3.69M derived: sum of 3 quarters · filed 2014-03-17 | $3.69M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $3.69M derived: sum of 2 quarters · filed 2014-03-17 | $3.69M derived: sum of 3 quarters · filed 2014-03-17 | $28.01M 10-K · filed 2014-03-17 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $144.00 derived: sum of 2 quarters · filed 2012-11-07 | $24.32M 10-Q · filed 2012-11-07 | $26.11M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $144.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $24.32M 10-Q · filed 2012-08-09 | $26.11M derived: sum of 3 quarters · filed 2013-03-18 | $25.72M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $24.32M 10-Q · filed 2012-05-09 | $26.11M derived: sum of 2 quarters · filed 2013-03-18 | $25.72M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $1.39M derived: sum of 2 quarters · filed 2013-03-18 | -$9.69M 10-K · filed 2013-03-18 | |
| 2010-09-30 | -$398.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$11.48M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$11.09M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $28.60M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |